These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 9834000)
1. Antiproliferative and cytotoxic effects of geldanamycin, cytochalasin E, suramin and thiacetazone in human prostate xenograft tumor histocultures. Gan Y; Au JL; Lu J; Wientjes MG Pharm Res; 1998 Nov; 15(11):1760-6. PubMed ID: 9834000 [TBL] [Abstract][Full Text] [Related]
2. Androgen-dependent and -independent human prostate xenograft tumors as models for drug activity evaluation. Chen CT; Gan Y; Au JL; Wientjes MG Cancer Res; 1998 Jul; 58(13):2777-83. PubMed ID: 9661891 [TBL] [Abstract][Full Text] [Related]
3. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. Thalmann GN; Sikes RA; Chang SM; Johnston DA; von Eschenbach AC; Chung LW J Natl Cancer Inst; 1996 Jun; 88(12):794-801. PubMed ID: 8637045 [TBL] [Abstract][Full Text] [Related]
4. Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors. Zhang Y; Song S; Yang F; Au JL; Wientjes MG J Pharmacol Exp Ther; 2001 Nov; 299(2):426-33. PubMed ID: 11602651 [TBL] [Abstract][Full Text] [Related]
5. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. Agus DB; Scher HI; Higgins B; Fox WD; Heller G; Fazzari M; Cordon-Cardo C; Golde DW Cancer Res; 1999 Oct; 59(19):4761-4. PubMed ID: 10519379 [TBL] [Abstract][Full Text] [Related]
6. 17-ABAG, a novel geldanamycin derivative, inhibits LNCaP-cell proliferation through heat shock protein 90 inhibition. Lin Z; Peng R; Li Z; Wang Y; Lu C; Shen Y; Wang J; Shi G Int J Mol Med; 2015 Aug; 36(2):424-32. PubMed ID: 26059743 [TBL] [Abstract][Full Text] [Related]
7. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer. Sirotnak FM; She Y; Lee F; Chen J; Scher HI Clin Cancer Res; 2002 Dec; 8(12):3870-6. PubMed ID: 12473602 [TBL] [Abstract][Full Text] [Related]
8. Tumor apoptosis induced by epoxide-containing piperazines, a new class of anti-cancer agents. Eilon GF; Gu J; Slater LM; Hara K; Jacobs JW Cancer Chemother Pharmacol; 2000; 45(3):183-91. PubMed ID: 10663635 [TBL] [Abstract][Full Text] [Related]
9. Preclinical antitumor activity of the oral platinum analog satraplatin. Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592 [TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of doxorubicin in human prostate tumors. Chen CT; Au JL; Wientjes MG Clin Cancer Res; 1998 Feb; 4(2):277-82. PubMed ID: 9516911 [TBL] [Abstract][Full Text] [Related]
11. Apoptosis: therapeutic significance in the treatment of androgen-dependent and androgen-independent prostate cancer. Kyprianou N World J Urol; 1994; 12(6):299-303. PubMed ID: 7881465 [TBL] [Abstract][Full Text] [Related]
12. Androgenic regulation of growth factor and growth factor receptor expression in the CWR22 model of prostatic adenocarcinoma. Myers RB; Oelschlager D; Manne U; Coan PN; Weiss H; Grizzle WE Int J Cancer; 1999 Jul; 82(3):424-9. PubMed ID: 10399960 [TBL] [Abstract][Full Text] [Related]
13. Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1. Amler LC; Agus DB; LeDuc C; Sapinoso ML; Fox WD; Kern S; Lee D; Wang V; Leysens M; Higgins B; Martin J; Gerald W; Dracopoli N; Cordon-Cardo C; Scher HI; Hampton GM Cancer Res; 2000 Nov; 60(21):6134-41. PubMed ID: 11085537 [TBL] [Abstract][Full Text] [Related]
14. Proton MRS detects metabolic changes in hormone sensitive and resistant human prostate cancer models CWR22 and CWR22r. Le HC; Lupu M; Kotedia K; Rosen N; Solit D; Koutcher JA Magn Reson Med; 2009 Nov; 62(5):1112-9. PubMed ID: 19780165 [TBL] [Abstract][Full Text] [Related]
15. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Nagabhushan M; Miller CM; Pretlow TP; Giaconia JM; Edgehouse NL; Schwartz S; Kung HJ; de Vere White RW; Gumerlock PH; Resnick MI; Amini SB; Pretlow TG Cancer Res; 1996 Jul; 56(13):3042-6. PubMed ID: 8674060 [TBL] [Abstract][Full Text] [Related]
16. FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer. Chua CW; Lee DT; Ling MT; Zhou C; Man K; Ho J; Chan FL; Wang X; Wong YC Int J Cancer; 2005 Dec; 117(6):1039-48. PubMed ID: 15986440 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of suramin against human prostate carcinoma DU145 xenografts in nude mice. Church D; Zhang Y; Rago R; Wilding G Cancer Chemother Pharmacol; 1999; 43(3):198-204. PubMed ID: 9923549 [TBL] [Abstract][Full Text] [Related]
18. Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases. Song S; Wientjes MG; Walsh C; Au JL Cancer Res; 2001 Aug; 61(16):6145-50. PubMed ID: 11507065 [TBL] [Abstract][Full Text] [Related]
19. Androgen receptor up-regulates insulin-like growth factor binding protein-5 (IGFBP-5) expression in a human prostate cancer xenograft. Gregory CW; Kim D; Ye P; D'Ercole AJ; Pretlow TG; Mohler JL; French FS Endocrinology; 1999 May; 140(5):2372-81. PubMed ID: 10218991 [TBL] [Abstract][Full Text] [Related]